Cargando…
Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation
(1) Background: survivors of allogeneic hematopoietic cell transplantation (alloHCT) suffer from morbidity and mortality due to cardiovascular events. We hypothesized that vascular injury and pro-coagulant activity are evident in alloHCT survivors without existing alloHCT complications or relapse. (...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767425/ https://www.ncbi.nlm.nih.gov/pubmed/33371421 http://dx.doi.org/10.3390/ijms21249768 |
_version_ | 1783628955582988288 |
---|---|
author | Gavriilaki, Eleni Sakellari, Ioanna Anyfanti, Panagiota Batsis, Ioannis Vardi, Anna Bousiou, Zoi Lazaridis, Antonios Nikolaidou, Barbara Zarifis, Ippokratis Masmanidou, Marianna Yiannaki, Efthalia Markala, Dimitra Anagnostopoulos, Achilles Douma, Stella Gkaliagkousi, Eugenia |
author_facet | Gavriilaki, Eleni Sakellari, Ioanna Anyfanti, Panagiota Batsis, Ioannis Vardi, Anna Bousiou, Zoi Lazaridis, Antonios Nikolaidou, Barbara Zarifis, Ippokratis Masmanidou, Marianna Yiannaki, Efthalia Markala, Dimitra Anagnostopoulos, Achilles Douma, Stella Gkaliagkousi, Eugenia |
author_sort | Gavriilaki, Eleni |
collection | PubMed |
description | (1) Background: survivors of allogeneic hematopoietic cell transplantation (alloHCT) suffer from morbidity and mortality due to cardiovascular events. We hypothesized that vascular injury and pro-coagulant activity are evident in alloHCT survivors without existing alloHCT complications or relapse. (2) Methods: we enrolled consecutive adult alloHCT survivors without established cardiovascular disease and control individuals matched for traditional cardiovascular risk factors (January–December 2019). Circulating microvesicles (MVs) of different cellular origins (platelet, erythrocyte, and endothelial) were measured by a standardized flow cytometry protocol as novel markers of vascular injury and pro-coagulant activity. (3) Results: we recruited 45 survivors after a median of 2.3 (range 1.1–13.2) years from alloHCT, and 45 controls. The majority of patients suffered from acute (44%) and/or chronic (66%) graft-versus-host disease (GVHD). Although the two groups were matched for traditional cardiovascular risk factors, alloHCT survivors showed significantly increased platelet and erythrocyte MVs compared to controls. Within alloHCT survivors, erythrocyte MVs were significantly increased in patients with a previous history of thrombotic microangiopathy. Interestingly, endothelial MVs were significantly increased only in alloHCT recipients of a myeloablative conditioning. Furthermore, MVs of different origins showed a positive association with each other. (4) Conclusions: endothelial dysfunction and increased thrombotic risk are evident in alloHCT recipients long after alloHCT, independently of traditional cardiovascular risk factors. An apparent synergism of these pathophysiological processes may be strongly involved in the subsequent establishment of cardiovascular disease. |
format | Online Article Text |
id | pubmed-7767425 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77674252020-12-28 Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation Gavriilaki, Eleni Sakellari, Ioanna Anyfanti, Panagiota Batsis, Ioannis Vardi, Anna Bousiou, Zoi Lazaridis, Antonios Nikolaidou, Barbara Zarifis, Ippokratis Masmanidou, Marianna Yiannaki, Efthalia Markala, Dimitra Anagnostopoulos, Achilles Douma, Stella Gkaliagkousi, Eugenia Int J Mol Sci Article (1) Background: survivors of allogeneic hematopoietic cell transplantation (alloHCT) suffer from morbidity and mortality due to cardiovascular events. We hypothesized that vascular injury and pro-coagulant activity are evident in alloHCT survivors without existing alloHCT complications or relapse. (2) Methods: we enrolled consecutive adult alloHCT survivors without established cardiovascular disease and control individuals matched for traditional cardiovascular risk factors (January–December 2019). Circulating microvesicles (MVs) of different cellular origins (platelet, erythrocyte, and endothelial) were measured by a standardized flow cytometry protocol as novel markers of vascular injury and pro-coagulant activity. (3) Results: we recruited 45 survivors after a median of 2.3 (range 1.1–13.2) years from alloHCT, and 45 controls. The majority of patients suffered from acute (44%) and/or chronic (66%) graft-versus-host disease (GVHD). Although the two groups were matched for traditional cardiovascular risk factors, alloHCT survivors showed significantly increased platelet and erythrocyte MVs compared to controls. Within alloHCT survivors, erythrocyte MVs were significantly increased in patients with a previous history of thrombotic microangiopathy. Interestingly, endothelial MVs were significantly increased only in alloHCT recipients of a myeloablative conditioning. Furthermore, MVs of different origins showed a positive association with each other. (4) Conclusions: endothelial dysfunction and increased thrombotic risk are evident in alloHCT recipients long after alloHCT, independently of traditional cardiovascular risk factors. An apparent synergism of these pathophysiological processes may be strongly involved in the subsequent establishment of cardiovascular disease. MDPI 2020-12-21 /pmc/articles/PMC7767425/ /pubmed/33371421 http://dx.doi.org/10.3390/ijms21249768 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gavriilaki, Eleni Sakellari, Ioanna Anyfanti, Panagiota Batsis, Ioannis Vardi, Anna Bousiou, Zoi Lazaridis, Antonios Nikolaidou, Barbara Zarifis, Ippokratis Masmanidou, Marianna Yiannaki, Efthalia Markala, Dimitra Anagnostopoulos, Achilles Douma, Stella Gkaliagkousi, Eugenia Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation |
title | Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation |
title_full | Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation |
title_fullStr | Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation |
title_full_unstemmed | Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation |
title_short | Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation |
title_sort | assessment of endothelial injury and pro-coagulant activity using circulating microvesicles in survivors of allogeneic hematopoietic cell transplantation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767425/ https://www.ncbi.nlm.nih.gov/pubmed/33371421 http://dx.doi.org/10.3390/ijms21249768 |
work_keys_str_mv | AT gavriilakieleni assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT sakellariioanna assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT anyfantipanagiota assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT batsisioannis assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT vardianna assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT bousiouzoi assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT lazaridisantonios assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT nikolaidoubarbara assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT zarifisippokratis assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT masmanidoumarianna assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT yiannakiefthalia assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT markaladimitra assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT anagnostopoulosachilles assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT doumastella assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation AT gkaliagkousieugenia assessmentofendothelialinjuryandprocoagulantactivityusingcirculatingmicrovesiclesinsurvivorsofallogeneichematopoieticcelltransplantation |